BioVersys and Shionogi have entered a research and exclusive licence option agreement for the co-development of new ansamycin ...

US-Japan venture capital firm AN Venture Partners has wrapped up its first fund at $200 million, marking one of the largest ...

Stallergenes Greer, Shionogi & Co., Ltd. ("Shionogi") and CEOLIA Pharma Co. Ltd ("CEOLIA") today announced the transition of promotional activities for Actair® in Japan. Actair® is Stallergenes ...

BioVersys & Shionogi ink global research collaboration for broad-spectrum NTM clinical candidate: Basel, Switzerland Thursday, July 3, 2025, 10:00 Hrs [IST] BioVersys AG, a multi- ...

There will be another ‘COVID’. Governments are planning for it, but how coordinated is that planning, and how resilient will ...

Following its acquisition by Supernus Pharmaceuticals, Sage Therapeutics has let go of all of its remaining workforce, which ...

Antibiotics specialist Bioversys AG has sealed a potential CHF529 million (US$667.5 million) deal with Shionogi Co. Ltd., in which they will work together on novel ansamycins for treating ...

Shionogi will pay BioVersys $6.3 million for developing BV500, BioVersys's drug candidate for non-tuberculous mycobacteria.

Some 9,196 recreational athletes swam across Lake Zurich on Wednesday in waters measuring 27 degrees Celcius. The event was ...

Swiss waters have warmed up considerably due to the hot weather. Over the last two weeks, lake temperatures have risen by an ...